DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of Cabergoline on Weight and Glucose Tolerance

Information source: Columbia University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Body Weight; Impaired Glucose Tolerance in Obese

Intervention: Cabergoline (Drug); placebo (Other)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Columbia University

Official(s) and/or principal investigator(s):
Judith Korner, MD, PHD, Principal Investigator, Affiliation: Columbia University


The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults. This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks. The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

Clinical Details

Official title: Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)

Primary outcome: body weight

Secondary outcome: glucose


Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.


Inclusion Criteria:

- age 18 - 55 years

- BMI 30 -40

Exclusion Criteria:

- diabetes,

- clinically significant medical condition,

- use of medications that effect blood glucose or body weight

Locations and Contacts

Columbia University, New York, New York 10032, United States
Additional Information

Starting date: April 2002
Last updated: July 31, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017